Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer
This newsletter presents you the following key sessions:
1. Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer
Medical writer
Medical writer
Medical writer